Literature DB >> 2883274

Somatostatin limits rise in glomerular filtration rate after a protein meal.

B H Brouhard, L F LaGrone, G E Richards, L B Travis.   

Abstract

To evaluate the glomerular filtration rate (GFR) response to a protein meal in patients with diabetes and to study the role of glucagon and growth hormone, we studied inulin clearance for three 30-minute periods before and 3 hours after an 80 g protein meal in seven healthy volunteers and 10 patients with diabetes. Patients with diabetes were chosen because their renal response to such a meal has been reported to be abnormal. All had an increase in GFR and plasma glucagon levels after the protein meal. The peak rise in GFR occurred from 1 to 2 1/2 hours after the meal (mean +/- SEM, delta 26 +/- 5 mL/min/m2, controls; delta 22 +/- 7 mL/min/m2, patients with diabetes), with the mean time to normal rise in GFR occurring at 2 hours after the meal. Similarly, plasma glucagon values peaked at different times in individual patients (delta 769 +/- 532 pg/mL, controls; delta 267 +/- 69 pg/mL, patients with diabetes), with the mean plasma glucagon rise occurring 1 hours after the meal. Premeal growth hormone levels tended to be higher in the patients with diabetes (7.6 +/- 1.4 vs 2.1 +/- 0.4 ng/mL), and did not change after the meal. To allow study of the contribution of the increased plasma glucagon to the rise in GFR, eight of these patients (five with diabetes) volunteered to undergo a second GFR response test with a simultaneous infusion of somatostatin. The glucagon response was significantly lowered at all time periods during the infusion (P less than 0.05); no significant change in growth hormone occurred. Without somatostatin in these eight patients, peak increase in postmeal GFR average 20.6 +/- 1.5 mL/min/m2; with the somatostatin, peak increase in GFR was 6.0 +/- 1.8 mL/min/m2 (P less than 0.01). Neither metabolic control nor degree of albuminuria was significantly different at the time of the two studies. Thus, as has been shown in animals, somatostatin infusion limits the rise in GFR after a protein meal in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883274     DOI: 10.1016/s0022-3476(87)80011-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

Review 1.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  An approach to protein restriction in children with renal insufficiency.

Authors:  N G Raymond; J T Dwyer; P Nevins; P Kurtin
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 3.  Glomerular hyperfiltration.

Authors:  Monica Cortinovis; Norberto Perico; Piero Ruggenenti; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2022-04-01       Impact factor: 42.439

4.  Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Norberto Perico; Piero Ruggenenti; Annalisa Perna; Anna Caroli; Matias Trillini; Sandro Sironi; Antonio Pisani; Eleonora Riccio; Massimo Imbriaco; Mauro Dugo; Giovanni Morana; Antonio Granata; Michele Figuera; Flavio Gaspari; Fabiola Carrara; Nadia Rubis; Alessandro Villa; Sara Gamba; Silvia Prandini; Monica Cortinovis; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  PLoS Med       Date:  2019-04-05       Impact factor: 11.069

5.  Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.

Authors:  Joshua Griffiths; Mark T Mills; Albert Cm Ong
Journal:  BMJ Open       Date:  2020-01-09       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.